Astria Therapeutics (NASDAQ:ATXS) Reaches New 52-Week High – Time to Buy?

Astria Therapeutics, Inc. (NASDAQ:ATXS)’s share price reached a new 52-week high on Wednesday . The company traded as high as $13.29 and last traded at $13.2040, with a volume of 548728 shares changing hands. The stock had previously closed at $12.93.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Citizens Jmp downgraded shares of Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 15th. HC Wainwright downgraded Astria Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 16th. Cantor Fitzgerald downgraded Astria Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Wednesday, November 12th. Wedbush set a $13.00 target price on Astria Therapeutics and gave the company a “neutral” rating in a research report on Wednesday, October 15th. Finally, Evercore ISI reiterated an “outperform” rating and set a $26.00 price target on shares of Astria Therapeutics in a report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Astria Therapeutics currently has an average rating of “Hold” and an average price target of $24.50.

Astria Therapeutics Price Performance

The company has a market capitalization of $753.46 million, a P/E ratio of -6.17 and a beta of 0.01. The firm has a fifty day moving average price of $12.72 and a 200-day moving average price of $9.30.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.14). The business had revenue of $0.71 million during the quarter, compared to analyst estimates of $10.67 million. On average, research analysts forecast that Astria Therapeutics, Inc. will post -1.65 EPS for the current year.

Institutional Trading of Astria Therapeutics

A number of large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. increased its holdings in Astria Therapeutics by 10,311.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,540 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 3,506 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in Astria Therapeutics by 185.8% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 3,557 shares during the period. Brevan Howard Capital Management LP purchased a new stake in shares of Astria Therapeutics during the third quarter worth $98,000. AXQ Capital LP purchased a new stake in shares of Astria Therapeutics during the third quarter worth $115,000. Finally, Bailard Inc. bought a new position in shares of Astria Therapeutics in the second quarter worth $142,000. 98.98% of the stock is owned by hedge funds and other institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders.